Skip to main content
. 2022 Mar 28;24(6):1159–1165. doi: 10.1111/dom.14688

FIGURE 2.

FIGURE 2

Insulin secretion‐plasma glucose dose‐response curves at baseline and 26 weeks in the iGlarLixi and GLP‐1RA arms. Plots are mean ± standard error of the mean. GLP‐1RA, glucagon‐like peptide 1 receptor agonist; iGlarLixi, insulin glargine 100 U/ml + lixisenatide